Micro-Flow Imaging multi-instrument evaluation for sub-visible particle detection.
暂无分享,去创建一个
P. Garidel | M. Blech | A. Boehrer | I. Fawaz | Simone Schaz
[1] A. Levačić,et al. Combining Machine Learning and Backgrounded Membrane Imaging: A case Study in Comparing and Classifying Different types of Biopharmaceutically Relevant Particles , 2022, Journal of pharmaceutical sciences.
[2] Melissa S. Murphy,et al. Qualitative high-throughput analysis of subvisible particles in biological formulations using backgrounded membrane imaging. , 2022, Journal of pharmaceutical sciences.
[3] Patrick Garidel,et al. Particle Detection and Characterization for Biopharmaceutical Applications: Current Principles of Established and Alternative Techniques , 2020, Pharmaceutics.
[4] M. Xia,et al. Interactions between polystyrene particles with diameters of several tens to hundreds of micrometers at the oil-water interface. , 2019, Journal of colloid and interface science.
[5] S. Im,et al. Direct measurement of electrostatic interactions between poly(methyl methacrylate) microspheres with optical laser tweezers. , 2019, Soft matter.
[6] A. Koulov,et al. Variance Between Different Light Obscuration and Flow Imaging Microscopy Instruments and the Impact of Instrument Calibration. , 2019, Journal of pharmaceutical sciences.
[7] S. Uchiyama,et al. Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium. , 2019, Journal of pharmaceutical sciences.
[8] T. Menzen,et al. Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development. , 2019, Journal of pharmaceutical sciences.
[9] Liling Zhang,et al. Closing the Gap: Counting and Sizing of Particles Across Submicron Range by Flow Cytometry in Therapeutic Protein Products. , 2017, Journal of pharmaceutical sciences.
[10] Lars V. Schäfer,et al. High‐concentration protein formulations: How high is high? , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[11] C. Probst,et al. Characterization of Protein Particles in Therapeutic Formulations Using Imaging Flow Cytometry. , 2017, Journal of pharmaceutical sciences.
[12] Nathaniel R Maddux,et al. Microflow Imaging Analyses Reflect Mechanisms of Aggregate Formation: Comparing Protein Particle Data Sets Using the Kullback-Leibler Divergence. , 2017, Journal of pharmaceutical sciences.
[13] Zuben E. Sauna,et al. Recent advances in (therapeutic protein) drug development , 2017, F1000Research.
[14] M. A. Neelakantan,et al. Synthesis, structure information, DNA/BSA binding affinity and in vitro cytotoxic studies of mixed ligand copper(II) complexes containing a phenylalanine derivative and diimine co-ligands. , 2016, Journal of photochemistry and photobiology. B, Biology.
[15] J. Gross,et al. Nanoparticle tracking analysis of particle size and concentration detection in suspensions of polymer and protein samples: Influence of experimental and data evaluation parameters. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[16] A. Koulov,et al. Factors Governing the Precision of Subvisible Particle Measurement Methods – A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe , 2016, Pharmaceutical Research.
[17] Tony Lubiniecki,et al. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. , 2015, Biologicals : journal of the International Association of Biological Standardization.
[18] Hanns-Christian Mahler,et al. Sterile Filtration of Highly Concentrated Protein Formulations: Impact of Protein Concentration, Formulation Composition, and Filter Material. , 2015, Journal of pharmaceutical sciences.
[19] Tony Lubiniecki,et al. Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy. , 2015, Journal of pharmaceutical sciences.
[20] Zhishang Hu,et al. An interlaboratory comparison of sizing and counting of subvisible particles mimicking protein aggregates. , 2015, Journal of pharmaceutical sciences.
[21] Samir Mitragotri,et al. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.
[22] W. Jiskoot,et al. Flow Imaging Microscopy for Protein Particle Analysis—A Comparative Evaluation of Four Different Analytical Instruments , 2013, The AAPS Journal.
[23] W. Jiskoot,et al. Micro-flow imaging and resonant mass measurement (Archimedes)--complementary methods to quantitatively differentiate protein particles and silicone oil droplets. , 2013, Journal of pharmaceutical sciences.
[24] G. Winter,et al. How subvisible particles become invisible-relevance of the refractive index for protein particle analysis. , 2013, Journal of pharmaceutical sciences.
[25] T. Das. Protein Particulate Detection Issues in Biotherapeutics Development—Current Status , 2012, AAPS PharmSciTech.
[26] Wim Jiskoot,et al. Particles in therapeutic protein formulations, Part 1: overview of analytical methods. , 2012, Journal of pharmaceutical sciences.
[27] Linda O Narhi,et al. Classification of protein aggregates. , 2012, Journal of pharmaceutical sciences.
[28] P. Garidel,et al. Microscopic Methods for Particle Characterization in Protein Pharmaceuticals , 2012 .
[29] A. Koulov,et al. Discrimination Between Silicone Oil Droplets and Protein Aggregates in Biopharmaceuticals: A Novel Multiparametric Image Filter for Sub-visible Particles in Microflow Imaging Analysis , 2012, Pharmaceutical Research.
[30] J. Vermant,et al. Heterogeneity of the electrostatic repulsion between colloids at the oil–water interface , 2010 .
[31] Patrick Garidel,et al. Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development , 2010, Pharmaceutical Research.
[32] S. Shire,et al. Characterization of Particles in Protein Solutions: Reaching the Limits of Current Technologies , 2010, The AAPS Journal.
[33] S. Singh,et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.
[34] D. K. Sharma,et al. Micro-Flow Imaging: Flow Microscopy Applied to Sub-visible Particulate Analysis in Protein Formulations , 2010, The AAPS Journal.
[35] M. Sukumar,et al. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging. , 2010, Journal of pharmaceutical sciences.
[36] Wei Wang,et al. Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.
[37] Vasco Filipe,et al. Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates , 2010, Pharmaceutical Research.
[38] P. Garidel,et al. Protein Therapeutics and Aggregates Characterized By Photon Correlation Spectroscopy An Application for High-Concentration Liquid Formulations , 2010 .
[39] Chi-Ting Huang,et al. Quantitation of protein particles in parenteral solutions using micro-flow imaging. , 2009, Journal of pharmaceutical sciences.
[40] Hanns-Christian Mahler,et al. Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.
[41] L. Narhi,et al. A critical review of analytical methods for subvisible and visible particles. , 2009, Current pharmaceutical biotechnology.
[42] T. Arakawa,et al. Mechanisms of protein aggregation. , 2009, Current pharmaceutical biotechnology.
[43] E. Thormann,et al. Interactions between a polystyrene particle and hydrophilic and hydrophobic surfaces in aqueous solutions. , 2008, Langmuir : the ACS journal of surfaces and colloids.
[44] Fred Jacobson,et al. Protein aggregation and bioprocessing , 2006, The AAPS Journal.
[45] A. Rosenberg,et al. Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.
[46] David E. Golan,et al. Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.
[47] G. Fuller,et al. Mechanical properties and structure of particle coated interfaces: influence of particle size and bidisperse 2D suspensions. , 2007, Langmuir : the ACS journal of surfaces and colloids.
[48] D. Forciniti,et al. Aggregation and denaturation of antibodies: a capillary electrophoresis, dynamic light scattering, and aqueous two-phase partitioning study. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[49] Huub Schellekens,et al. Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.
[50] A. Fernandez-Barbero,et al. The aggregation behaviour of protein-coated particles: a light scattering study , 2003, European Biophysics Journal.
[51] Stavros Kromidas,et al. Handbuch Validierung in der Analytik , 2000 .
[52] A. Takahara,et al. Bovine serum albumin adsorption onto immobilized organotrichlorosilane surface: influence of the phase separation on protein adsorption patterns. , 1998, Journal of biomaterials science. Polymer edition.